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The revolution will be open-source: how 3D bioprinting can
change 3D cell culture
Robert D. Bruno, John Reid and Patrick C. Sachs
Comment on: Consistent and reproducible cultures of large-scale 3D mammary epithelial structures using an accessible bioprinting platform by Reid et al. Breast Cancer Research. 2018; 20:122. https://doi.org/10.1186/s13058-018-1045-4

The development of three-dimensional culture
scaffolds represents a revolutionary step forward for in
vitro culture systems. Various synthetic and naturally
occurring substrates have been developed that support
3D growth of cells. In most fields, including mammary
gland biology and tumorigenesis, the two most common
substrates used are the basement membrane rich
extracellur matrix (ECM) isolated from EngelbrethHolm-Swarm (EHS) mouse sarcomas (e.g. Matrigel) and
collagen extracted from rat-tails. The processes of 3D
culture in these two substrates has remained unchanged
for nearly half a century: cells are either mixed with
unpolymerized matrix to disperse them randomly
throughout the substrate upon polymerization or overlaid
randomly on top of a preformed hydrogel. While effective
in generating organoid/tumoroid structures, the random
nature of these processes has many drawbacks that limit
the reproducibility and tunability of the experimental
design. Furthermore, random cellular distributions limit
the utility of these substrates for studying interactions
within the cellular microenvironment, which have been
shown to be critical for the control of stem and cancer cell
function [1].
To overcome these issues, computer numerically
controlled (CNC) devices can be adapted to precisely
control cellular deposition within hydrogels. An example
of these devices can be found in the three-axis control of
modern 3D fusion deposition method (FDM) printers.
Despite a rapid drop in cost of 3D printing technology,
printers specifically engineered for bioprinting purposes
generally remain unattainably expensive for general
biological research laboratories. Thus the technology
has been limited to specific biofabrication applications
in specialty biomedical engineering laboratories.
Furthermore, commercially available bioprinters
are exclusively designed for printing “bioinks”
(unpolymerized scaffoldings with or without cells) into
shapes. While potentially useful for medical reconstructive
procedures, the shape of the hydrogel is meaningless to
cell biologists seeking to understand basic questions of
cell biology, or for engineering applications seeking to
direct specific differentiation of cells.
To this end, we recently developed a low-cost open
access 3D bioprinting system that can be used for scientists
applications (Figure 1) [2]. The printer is an open source
www.oncotarget.com

Figure 1: Custom benchtop 3D bioprinter and its
application for printing large mammary organoids.

Top: Image of an example 3D bioprinter constructed off of the
Felix 3.0 (FELIXrobotics, NL) platform. Middle: Example of
coordinated print of clusters of red fluorescent protein (RFP)
labeled MCF12a cells at distances of 200µm in linear array.
Image taken 24 hours post-print. Scale bar = 200µm. Bottom:
Mature organoid (21 days post-print) formed from coordinated
print of clusters of RFP MCF12a cells into a circular array.
Resulting organoids have been shown to have contiguous lumens
stretching > 3mm in length.
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project that allows other laboratories to build their own
system. Initially, all necessary parts can be printed using a
standard off-the-shelf 3D FDM printer. The same printer
can then be modified with these parts into a 3D bioprinter.
In essence, you can 3D print your own 3D bioprinter. This
system is designed to be adaptable to any application the
end user requires, and we have described its use for both
printing cells as well as guiding electrodes for directed
electrical pulsing of cells [3, 4]. To increase precision
and maintain integrity of printed cells, we use pulled
glass micropipette syringes as our cell injection “printhead” [2]. Compared to standard steel needles attached to
luer lock syringes, these glass micropipettes have a finer
point and reduce sheer force on the cells. Combined, this
minimizes disruptions to the cells and allows the hydrogel
to seal behind the print. Thus, our system allows for the
precise placement of cells, that then self-organize into
organoids/tumoroids, making functional structures [4].
This differs from many bioprinting approaches that print
cell free or cell-laden “bioinks” into 3D shapes. Again,
while these approachees are potentially useful for specific
medical reconstruction procedures, they have little utility
for most biological applications. For example, cells printed
in the shape of a mammary gland are not a mammary
gland; it is the coordinated function and differentiation of
cells through development that make tissues and organs
functional.
We have recently described the use of this system
for printing mammary organoids in standard 3D hydrogels
[4]. By depositing specific numbers of cells at controllable
distances we could guide the growth of organoids into
predictable sizes and shapes (Figure 1). The key to the
guided growth was the fact that mammary epithelial
cells (MCF12a and MCF10a) would preferentially grow
towards neighboring prints, forming single contiguous
organoids. Using this strategy, we generated large
contiguous luminal mammary organoids (> 5mm in
length). This is in clear contrast to random culture where
the dispersion of cells results in random organoid shape
and size, with organoids never forming more than a couple
of hundred microns in size. Controlling for organoid
distancing, shaping, and sizing is thus not feasible in
standard culture models and therefore interpretation
of studies where these factors may play a role becomes
difficult. This is particularly true for experiments on
microenvironmental forces and cancer/epithelial cell
growth. Because surrounding organoids can influence the
rigidity of the microenvironment, control of the placement,
spacing, and size is critical.
In an era of poor data reproducibility in science
[5], instruments and methods designed to limit lab-tolab variability are in need. The open source nature of our
bioprinter helps facilitate standardization of experimental
parameters across laboratories. This is because the
www.oncotarget.com

machine instructions or GCODE generated for printing
experiments can be shared once data is published. We have
shared our files through our website www.odustemcell.
org. Researchers can go to this website, download the
files needed to print their own bioprinter, and then use the
GCODE files necessary to repeat our experiments exactly
using their own bioprinter. While this certainly doesn’t
eliminate all inter-laboratory variability, it helps simplify
the process of reproducing an experiment.
Our current focused application of this printing
technology is to understand the role of the cellular
microenvironment in controlling differentiation of stem
and cancer cells (Reid et al., Submitted). We have explored
this topic in in vivo models [6–10], but our bioprinting
platform allows for mechanistic insights into the process.
These studies are ongoing, but one can imagine our
printing platform can be used to improve any application
where the random nature of traditional 3D culture is a
confounding variable. And, one could argue, nearly every
study is potentially confounded by this factor.
A common issue with modern science/scientist is the
tendency to assign radical ideas to the “science fiction”
classification; however, bioprinting needs not be the stuff
of science fiction. Our studies highlight the ease of access
and the utility of the technology for basic cell and cancer
biology studies. Thus, we hope to lower the bar of entry
further by developing easier-to-access solutions, such
as ready built kits, and a graphic user interface (GUI) to
simplify the experimental programming. The system offers
a potentially revolutionary step forward for 3D culture
models of development and cancer.
Robert D. Bruno: School of Medical Diagnostic &
Translational Sciences, Old Dominion University, Norfolk,
VA, USA
Correspondence to: Robert D. Bruno,
email rbruno@odu.edu

Patrick C. Sachs: School of Medical Diagnostic &
Translational Sciences, Old Dominion University, Norfolk,
VA, USA
Correspondence to: Patrick C. Sachs,
email psachs@odu.edu
Keywords: 3D bioprinting; 3D culture; mammary gland;
breast cancer; open-source
Received: April 03, 2019
Published: July 30, 2019

REFERENCES

4725

1.

Bruno RD, Smith GH. Semin Cell Dev Biol. 2012; 23:591598.
https://doi.org/10.1016/j.semcdb.2012.03.007.
[PubMed]

2.

Reid JA, et al. Biofabrication. 2016; 8:025017.

Oncotarget

https://doi.org/10.1088/1758-5090/8/2/025017. [PubMed]
3.

Petrella RA, et al. J Neural Eng. 2018; 15:056021.
https://doi.org/10.1088/1741-2552/aac8ec. [PubMed]

4.

Reid JA, et al. Breast Cancer Research. 2018; 20:122.
https://doi.org/10.1186/s13058-018-1045-4. [PubMed]

5.

Baker M. Nature. 2016; 533:452-454.

6.

Booth BW, et al. Proc Natl Acad Sci U S A. 2008;
105:14891-14896.

https://doi.org/10.1038/533452a. [PubMed]

https://doi.org/10.1073/pnas.0803214105. [PubMed]
7.

Bruno RD, et al. Scientific Reports. 2017; 7:40196.
https://doi.org/10.1038/srep40196. [PubMed]

8.

Sachs PC, et al. Cell and Tissue Research. 2012; 349:505515. https://doi.org/10.1007/s00441-012-1423-7. [PubMed]

9.

Zhao M, et al. Cancer Biol Ther. 2012; 13:782-792.
https://doi.org/10.4161/cbt.20561. [PubMed]

10. Sachs PC, et al. J Biol Eng. 2017; 11:34.
https://doi.org/10.1186/s13036-017-0077-0. [PubMed]
Copyright: Bruno et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License 3.0
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source
are credited.

www.oncotarget.com

4726

Oncotarget

